Sonnet Bio Spikes 70% In Pre-Market On FDA Covid-19 Plasma Nod
Monday, August 24, 2020 7:37 AM EDT
SONN is spiking 70% in Monday’s pre-market trading on news that the U.S. Food & Drug Administration (FDA) has granted an emergency authorization to use blood plasma from recovered Covid-19 patients as a treatment for the disease.
In this article: SONN